Indication

For the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

Medicine details

Medicine name:
siponimod (Mayzent)
SMC ID:
SMC2265
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
13 July 2020
SMC meeting date:
02 June 2020
Patient group submission deadline:
04 May 2020